CN100360684C - Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA - Google Patents
Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA Download PDFInfo
- Publication number
- CN100360684C CN100360684C CNB2005100377780A CN200510037778A CN100360684C CN 100360684 C CN100360684 C CN 100360684C CN B2005100377780 A CNB2005100377780 A CN B2005100377780A CN 200510037778 A CN200510037778 A CN 200510037778A CN 100360684 C CN100360684 C CN 100360684C
- Authority
- CN
- China
- Prior art keywords
- rna
- pipe
- water
- hydrochloric acid
- bottle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a fluorescent quantitative RT-PCR detecting kit of alpha-fetoprotein (AFP) mRNA. The kit comprises general RNA extracting solution (cell cracked solution I and II, RNA washing buffer I and II and water without RNA enzyme), inverse transcript reaction solution, a dNTP mixture, inverse transcriptase, PCR reaction solution, a probe, a positive criteria sample and a reference object. The present invention can be used for accurately and quantitatively detecting the expression quantity of mRNA of AFP in a specimen by means of exacting gross RNA from fresh anticoagulant peripheral blood, obtaining cDNA by a reverse transcription mRNA sample by combining real time quantitative PCR detection technology. The kit provided by the present invention can be used for detecting the expression of AFP mRNA in the peripheral blood, the marrow, the lymph nodes and cancer tissues of patients with tumors in clinic and scientific research. Thus, significant reference frames can be provided for the determination and the prognostic judgement of the early diagnosis, the transfer, the recurrence and the therapeutic regimen of primary liver cancers.
Description
Technical field
The invention belongs to biological technical field, for a kind of by fresh anticoagulation cirumferential blood is extracted total RNA, and obtain cDNA by reverse transcription mRNA sample, again in conjunction with the real-time fluorescence quantitative PCR detection technique, accurate alpha-fetoprotein (alpha-fetal protein, AFP) test kit of the expression amount of mRNA in the detection by quantitative sample.
Background technology
The invention belongs to biological technical field, for a kind of by fresh anticoagulation cirumferential blood is extracted total RNA, and obtain cDNA by reverse transcription mRNA sample, again in conjunction with the real-time fluorescence quantitative PCR detection technique, accurate alpha-fetoprotein (α-fetal protein, AFP) test kit of the expression amount of mRNA in the detection by quantitative sample.
Primary hepatocarcinoma is as one of China's common malignancy, and its sickness rate is in rising trend in recent years.According to the statistics of the Ministry of Health, playing primary hepatocarcinoma the nineties has become second cancer killer of China, is only second to lung cancer in the city, then is only second to cancer of the stomach in the rural area.Radical operation is the first-selection in the liver cancer complex therapy.So-called radical excision is that the broken ends of fractured bone and surplus liver do not have residual cancer and retain no distant metastasis, no cancer embolus behind the tumor resection; The postoperative alpha-fetoprotein can be reduced to normal value in 2 months.Yet when the excision technology had reached suitable maturation and popularized, the height recurrence and the rate of transform after the liver cancer excision became the major cause that hinders liver cancer patient raising lifetime.
At present, cause the high major cause of recurrence of PHC rate, it is liver cancer cell nature or because the aggressive iatrogenic factors drops to peripheral blood before the operation, and be transferred to outside the liver with blood, form circulating tumor cell, but because examined method sensitivity and specific restriction, this micro-cancer cells fails to detect.These cancer cells arrive peripheral tissues and are in dormant state with blood, when patient's body's immunity descends, as using the anti-immunosuppressor etc. of repelling after major operation or the liver transplantation, the cancer cells of dormancy just might be activated, and turn back to liver with blood circulation, and in liver, recover propagation, thereby caused the recurrence of liver cancer.Therefore circulating tumor cell and tumour cell mark are considered to blood dissemination and cause the predictability index of distant metastasis of human, find that in time the cyclicity tumour cell in the peripheral blood is not only significant to transfer, the recurrence of judging tumour, and to instructing clinical formulation treatment measure that guiding value is also arranged.
Alpha-fetoprotein is to be used for the special biomarker that liver cancer detects at present clinically.The selection of relevant liver cancer-specific mark once had human albumin mRNA to be present in index in the blood as detecting liver cancer cell.Find after deliberation, though albumin mainly is that peripheral blood leucocyte also can be expressed albumin mRNA by the liver cell secretion.Therefore, albumin mRNA can not be as the index of liver cancer cell existence in the reflection blood.AFP mRNA is proposed by Matsumura etc. at first as the hepatoma Metastasis mark, they use RT-PCR, and to detect peripheral blood APP mRNA positive rate be 52% (17/33), outer all positive (6/6) of shifting of liver is wherein arranged, and the positive rate that finds no the patient of metastasis is that the healthy people's contrast of 41% (11/27) .26 example is all negative.The positive rate of reports such as Komeda is 36% (23/64), and control group is all negative.Two researchs show that all normal healthy controls group peripheral blood AFP mRNA is all negative, illustrate that karyocyte is not expressed AFP mRNA in the blood, and it is very unstable to be free on extracellular mRNA, very easily by the RNA enzymolysis, so peripheral blood records in the AFP mRNA prompting circulation of blood and has complete liver cancer cell.Therefore, alpha-fetoprotein mRNA is the observation index of a reasonable haematogenous liver cancer cell.
The appearance of fluorescent quantitative PCR technique for we provide the accurate method of a detection by quantitative mRNA, to detecting cancer specific gene mRNA amount, has produced positive pushing effect to detect existing of circulating tumor cell.The quantitative assay of oncogene mRNA in the peripheral blood helps the early diagnosis of primary hepatocarcinoma, the judgement of the definite and prognosis of treatment plan.
Before fluorescent quantitative PCR technique produces, domestic detection about peripheral blood AFP mRNA still is in the qualitative examination stage, though it is positive to detect part liver cancer patient peripheral blood AFP mRNA, but can not accurately measure the expression level of AFP mRNA in these positive samples, be unsuitable for the tracking monitor of liver cancer patient.The real-time fluorescence quantitative PCR technology has been merged advantages such as the high precision of the high specific of PCR high sensitivity, DNA hybridization and spectroscopic techniques is quantitative, the variation of fluorescent signal is to obtain quantitative results in the direct detection PCR process, do not need PCR aftertreatment or electrophoresis detection, stopped pipe operation fully, one action has overcome many difficult problems of conventional round pcr.Compare with conventional PCR, following advantage is arranged: 1, can carry out detection by quantitative accurately, can be used for being suitable for the various diseases of gene diagnosis.With detection hepatitis B HBV-DNA commonly used at present is example, it can not only detect, and hepatitis B virus intravitally duplicates patient, infectious situation, the more important thing is can be as a quantized index, can detect the intravital viral number of patient quantitatively, dynamically observe the state of an illness course of disease, observe result of treatment, an index as clinical treatment, can judge curative effect of medication, instruct the clinicist to select active drug, determine medicament, dose and the course of treatment and analyze result of treatment, determine aspects such as further treatment plan, have important and realistic meanings.2, specificity is extremely strong, has overcome false-positive main source.3, quantitatively scope is extremely wide, and sample need not to do gradient dilution.4, operation need not the PCR aftertreatment, the level of automation height rapidly.
So-called real-time fluorescence quantitative PCR technology is meant in the PCR reaction system to add fluorophor, utilizes the fluorescent signal accumulation whole PCR process of monitoring in real time, carries out the method for quantitative analysis by typical curve to knowing template at last.In fluorescent quantitative PCR technique, common preceding 15 the round-robin fluorescent signals that react with PCR are as the fluorescence background signal, the default setting of fluorescence threshold is 10 times of standard deviation of 6-15 round-robin fluorescent signal, and the cycle number that is experienced when the fluorescent signal in each reaction tubes arrived preset threshold is made as the Ct value.Studies show that there is linear relationship in the logarithm of the Ct value of each template and the initial copy number of this template, initial copy number is many more, and the Ct value is more little.Utilize the standard substance of known initial copy number can make typical curve, wherein X-coordinate is represented the logarithm of initial copy number, and ordinate zou is represented the Ct value.Therefore, as long as obtain the Ct value of unknown sample, can calculate the initial copy number of this sample from typical curve.
When adding a pair of primer, add a specificity fluorescent probe in the real-time fluorescence quantitative PCR amplification procedure, commonly used is the Taqman fluorescent probe at present, this probe is an oligonucleotide, and two ends are mark report fluorophor and a cancellation fluorophor respectively.When probe was complete, the reporter group fluorescent signal emitted was absorbed by quenching group, so detect less than fluorescence; In the pcr amplification process, 5 '-3 ' 5 prime excision enzyme activity of Taq enzyme is cut degraded with the probe enzyme, the report fluorophor is separated with the cancellation fluorophor, thereby the fluorescence monitoring system can receive fluorescent signal.Each working cycle detection of end first order fluorescence intensity, reaction just can obtain a working curve after finishing.
Because quantitative fluorescent PCR has good reproducibility, highly sensitive, quantitative result is characteristics accurately and reliably, so in the medical science context of detection, the problem that some conventional sense methods cann't be solved has obtained solution.For example, the morphocytology inspection can directly observe tumour cell, get portal vein at intra-operative, extract karyocyte and do HE dyeing back microscopy, can find the tumour cell that comes off, but because the number that tumour drops in the circulation of blood is small, the susceptibility of this inspection and specificity are all relatively poor, and positive rate only is 1%.The application that immunohistochemical method has improved tumour cell painted specificity, particularly monoclonal antibody in the circulation of blood makes painted specificity and susceptibility that bigger improvement arranged, and can find 10
4-10
5A tumour cell in the individual karyocyte.But this technology then needs specific antibody, the production relative complex.Simultaneously, false positive has limited this broad application.This method of usefulness such as Matsumura fails to find tumour cell in the Patients with Primary peripheral blood, think that this method is not suitable for the detection of liver cancer micrometastasis.Compare with these technology, quantitative fluorescent PCR has tangible advantage, because the adjusting of most of genes betides transfer level, some tumour can be transcribed specific mrna, but it is synthetic not have corresponding protein, so the quantitative fluorescent PCR range of application is wider; PCR is simple and easy to do, as long as know the testing gene sequence, can design synthetic primer and carry out reverse transcription and amplification; This method has higher sensitivity and repeatability, has also guaranteed the accuracy of medical science detected result.So this The Application of Technology will be to the tumour cell in the circulation of blood of early stage searching Patients with Primary, find the outer small transfer of liver for guiding clinical treatment, improve patient's prognosis and produce very important effect.
Summary of the invention
Test kit of the present invention comprises: cell pyrolysis liquid I, cell pyrolysis liquid II, RNA lavation buffer solution I, RNA lavation buffer solution II, the water of no RNA enzyme, RNA separator column, reverse transcription damping fluid, reversed transcriptive enzyme storage liquid, dNTP mixture, PCR reaction solution, probe, standard substance, reference substance.More than various solution be the aqueous solution.
(1), cell pyrolysis liquid I comprises: 0.1mol/L Tris-HCl (Tutofusin tris-hydrochloric acid, pH7.6,25 ℃), 0.1mol/L sodium-chlor, 0.05mol/L magnesium chloride, water.
(2), cell pyrolysis liquid II comprises: 3mol/L guanidinium isothiocyanate, 2mol/L Guanidinium hydrochloride, 0.3mol/L sodium-acetate (pH5.2), 0.2% (W/V) SDS (sodium lauryl sulphate), water.
(3), RNA lavation buffer solution I:0.2mol/L sodium-acetate (pH5.2), 0.1mol/L sodium chlorate, 0.1mol/LTris-HCl (pH7.5,25 ℃), water.
(4), RNA lavation buffer solution II:1.2mol/L Trisodium Citrate, 0.5mol/L Tris-HCl (pH7.5,25 ℃), water.
(5), the water preparation method of no RNA enzyme adds DEPC (diethylpyrocarbonate) to deionized water, to final concentration be 0.05% (V/V), room temperature (22-25 ℃) was placed after 10-12 hour, 121 ℃, the 20min high pressure, room temperature is placed standby.
(6), the RNA separator column is a kind of silicagel column, available from U.S. Omega biotech company (Hibind-V post), this post adopts Hibind silica matrix film combination technology, can specificity in conjunction with RNA, and used water eluted rna reaches the purpose of separation and purification RNA.
(7), the reverse transcription damping fluid comprises: 9.1 μ mol/L Oligo (dT)
12-18, 3.6U/ μ l Rnase Inhibitor, 72.7mmol/L DTT (dithiothreitol (DTT)), 182mmol/L Tris-HCl (pH8.3,25 ℃), 273mmol/L KCl, 11mmol/L MgCl
2
(8), the reversed transcriptive enzyme storage liquid comprises: 20mmol/L Tris-HCl (pH7.5,25 ℃), 100mmol/L NaCl, 0.1mmol/L EDTA, 1.0mmol/L DTT, 50% (V/V) glycerine, 0.01% (V/V) Nonidet p-40,200U/ μ l reversed transcriptive enzyme (M-MLV), water.
(9), the dNTP mixture comprises: dATP, dCTP, dGTP, dTTP, be its sodium salt-aqueous solution pH7.0-7.5, four kinds of dNTP concentration are 10mmol/L.
As dATP is deoxyadenosine triphosphate, and its sodium salt is that in three hydrogen on the phosphoric acid one or two replaced by sodium, just formed sodium salt; Other are several also to be like this.Be that dNTP exists with sodium-salt form.
(10), the PCR reaction solution comprises: 18.5mmol/L Tris-HCl (pH8.3,25 ℃), 2.78mmol/L MgCI
2, 92.6mmol/L KCl, upstream and downstream primer (0.37 μ mol/L), 0.1U/ μ l Taq enzyme, dNTP mixture (dGTP, dTTP, its concentration is 400nmol/L for dATP, dCTP), water.
Detection is used the downstream primer sequence and is respectively:
P1：5’-TGA CTC CAG TAA ACC CTG GT-3’
P2：5’-AGA AAT CTG CAA TGA CAG CC-3’
(11), the probe of fluorescence probe mark, its sequence is:
5’-FAM-TGC TGC ACT TCT TCA TAT GCC AAC A-TAMRA-3’
The concentration of probe is: 2 μ mol/L, TE (10mmol/L Tris-HCl, 1mmol/L EDTA. water) dissolving.
(12), the sequence of standard substance is:
1 AGAAATCTGC AATGACAGCC TCAAGTTGTT CCTCTGTTAT TTGTGGCTTT
51 TGCTTCACAA GGTTAATGAG AAACTCTTGC TTCATCGTTT GCAGCGCTAC
101 ACCCTGAGCT TGGCACAGAT CCTTATGGAA AATGAACTTG TCATCAGAGA
151 ATGCAGGAGG GACATATGTT TCATCCACCA CCAAGCTGCT GAAGCATGGC
201 CTCCTGTTGG CATATGAAGA AGTGCAGCAC TGGCCAACAC CAGGGTTTAC
251 TGGAGTCA
The concentration of standard substance is: 10
6Copies/ μ l, TE (10mmol/L Tris-HCl, 1mmol/L EDTA, water) dissolving.
(13), reference substance is divided into positive reference substance and negative control product, positive reference substance is the sample (10 that AFP cDNA is arranged
4Copies/ μ l, the TE dissolving), the negative control product are the reverse transcription product of the total RNA of normal people's peripheral blood.
The specification of test kit of the present invention is: 10 person-portions/box; The amount of each component is in every box: cell pyrolysis liquid I1 bottle (30ml/ bottle), cell pyrolysis liquid II1 bottle (10ml/ bottle), RNA lavation buffer solution I1 bottle (10ml/ bottle), RNA lavation buffer solution II1 bottle (3ml/ bottle), 1 bottle in no RNA enzyme water (2ml/ bottle), RNA separator column (10), reverse transcription damping fluid 1 pipe (27.5ul/ pipe), dNTP mixture 1 pipe (5ul/ pipe), reversed transcriptive enzyme 1 pipe (2.5ul/ pipe), PCR reaction solution 1 pipe (216ul/ pipe), probe 1 pipe (24ul/ pipe), standard substance 1 pipe (10ul/ pipe), positive reference substance 1 pipe (10ul/ pipe), negative control product 1 pipe (10ul/ pipe).
This reagent total RNA extraction reagent is stored in room temperature (22-25 ℃); RT-PCR reagent is stored in-20 ℃, reduces multigelation as far as possible.
The present invention has set up the method for utilizing TaqMan technology for detection AFP mRNA to express, and patient's sample after testing, shows that this method is practical.Because present method has adopted the pcr amplification technology, the detection sensitivity that makes AFP mRNA express improves greatly, and because the application of fluorescent probe, make its specificity improve greatly, reduced the false positive rate of conventional pcr amplification, make us can obtain enough information in the sample of minute quantity, the total RNA extraction reagent among the present invention and at present conventional RNA extract the reagent following advantage of having compared: (1). and easy and simple to handle; (2). safe in utilization, operating process does not have organic solution and pollutes; (3). extract fully, sophistication and high-quality reagent guarantee that sample RNA extracts fully; (4). gained RNA purity height.Primer, probe and detected result that present method is designed can provide reliable foundation for the exploitation of fluorescent quantificationally PCR detecting kit.
In this test item, we have adopted present state-of-the-art real-time fluorescence quantitative PCR detection technique, reduce false-positive interference under the prerequisite that keeps hypersensitivity as far as possible.Before the real-time fluorescence quantitative PCR detection technique occurs, people quantitatively will pass through PCR product electrophoresis to pcr template, again with electrophoresis result machine picture processing as calculated, determine what of final PCR product amount according to the brightness of electrophoretic band, or the PCR product of the tape label mode with ELISA detected, infer the amount that starting template more thus, but these methods in fact all belong to the sxemiquantitative level, even because PCR condition optimization, the unstable of the operation of electrophoresis and subsequent step brings influence still can for result's analysis, thereby influences quantitative this purpose.Appearance along with the real-time fluorescence quantitative PCR technology, people can accomplish the accurate quantification to pcr template veritably, this high sensitivity that has quantitatively not only kept conventional PCR, and because specificity fluorescent probe hybridization The Application of Technology makes the specificity of detected gene improve greatly.
The using method of test kit of the present invention:
Each detection all should be set up positive control and negative control.
[sample requirement]
The fresh peripheral blood or the sample of bone marrow of 3 milliliters of EDTA anti-freezings.
Adopt venous blood or marrow 3ml in 5 or the aseptic centrifuge tube of 10ml in, use EDTA to make antithrombotics (1.44mg/ml whole blood).Should use immediately after the sample collection, if can not use immediately, can preserve 1-2 hour, but the time should not be after length, otherwise will influence measurement result at 4 ℃.Whole blood after treatment, the karyocyte that obtains can be stored in the several months in-80 ℃ or the liquid nitrogen, can not influence measurement result.
[operation steps]
One, experiment is prepared
1. cell pyrolysis liquid I is diluted to cell pyrolysis liquid I diluent in 1: 10 ratio with the sterilization deionized water.
2. add 2 mercapto ethanol in cell pyrolysis liquid II, add-on is the 2 mercapto ethanol (concentration of commercial solution is generally 14.5mM) that every 1ml cell pyrolysis liquid II adds 20 μ l, and the packing 2 mercapto ethanol will carry out under ventilating kitchen.
3.RNA the indication that lavation buffer solution II before using, presses on the label adds dehydrated alcohol.
Two, total RNA extracts
1. the cell pyrolysis liquid I diluent that in the 50ml centrifuge tube of handling once autoclaving, adds fresh anticoagulated blood of 3ml and 15ml, the vortex oscillation mixing.
2. ice bath is 15 minutes, rapid mixing twice on the vortex oscillation device, and the solution becomes clarification shows red corpuscle cracking.If the hemocytometer of individual samples when perhaps ECR raises, can prolong ice bath time to 20 minute.
3.4 ℃, 450g, centrifugal 10 minutes precipitation karyocytes discard the supernatant that contains splitting erythrocyte fully.
4. with the cell pyrolysis liquid I diluent washing precipitation karyocyte of 6ml, vortex oscillation is with complete suspension cell.
5.4 ℃, 450g, centrifugal 10 minutes, and remove supernatant once more.
6. add 650 μ l cell pyrolysis liquid II (having added 2 mercapto ethanol) in agglomerating karyocyte, the abundant mixing of vortex oscillation is transferred to the 1.5ml centrifuge tube of a no RNA enzyme with it.
7. add isopyknic 70% ethanol, the vortex oscillation mixing.May produce throw out this moment owing to alcoholic acid adds, but this can not influence the extraction of RNA.
8. above-mentioned mixed solution (not comprising precipitation) is added to that (this post maximum binding capacity is 800 μ l on the RNA separator column that is fixed on the 2ml collection tube, so each amount that adds should not surpass 750 μ l), 10000g centrifugal 1 minute, discards flowing liquid and proceeds the operation of step 8.
9. drawing 750 μ l RNA lavation buffer solution I directly is added on the RNA separator column and washs pillar.As above method is centrifugal and discard the 2ml collection tube.
10. pillar is installed to new 2ml collection tube, add the RNA lavation buffer solution II of 500 μ l with alcohol dilution, 10000g, centrifugal 1 minute, discard effluent liquid, reuse this collection tube.
11. it is, centrifugal and discard effluent liquid again with the RNA lavation buffer solution II of 500 μ l washing pillar.The centrifugal pillar of 12000g dried RNA separator column matrix in 1 minute one then.
12. eluted rna.The water elution RNA that posts transfer is not also had the RNA enzyme to the 1.5ml centrifuge tube (test kit does not provide) of no RNA enzyme with 50 l.The water of guaranteeing the no RNA enzyme that adds directly is added on the base for post matter centrifugal 1 minute of 10000g.Place on the ice chest centrifuge tube that RNA is housed standby.
Three, RT-PCR
1. the centrifuge tube that reverse transcription damping fluid, dNTP mixture, reversed transcriptive enzyme storage liquid will be housed takes out from-20 ℃, place treat on the ice chest that it slowly melts after, of short duration centrifugal, with pipettor dNTP mixture and reversed transcriptive enzyme storage liquid are all added in the reverse transcription damping fluid pipe and to be mixed with inverse transcription reaction liquid, mixing, of short duration centrifugal, place on the ice chest standbyly, use back residue inverse transcription reaction liquid can put into-20 ℃ of refrigerators and preserve.
According to the form below preparation reverse transcription system
Inverse transcription reaction liquid 3.5ul
Total rna solution 2.0ul
The water 4.5ul of no RNA enzyme
The reverse transcription reaction condition: 50 ℃ 10 minutes, take out and to place on the ice chest.
2. by following composition preparation PCR reaction solution:
Reverse transcription product 10ul
PCR reaction solution 13.5ul
Probe 1.5ul
The PCR reaction conditions: 95 ℃ 10 minutes; (95 ℃ 15 seconds, 60 ℃ 1 minute, 50 circulations).
Four, the making of typical curve
With standard substance stock solution (2 * 10
6Copies/ul) gradient dilution is 2 * 10
5, 2 * 10
4, 2 * 10
3, 2 * 10
2, 2 * 10
1Copies/ul, getting 5ul is that template (adding water 5ul, the same table of other components) is together carried out pcr amplification with testing sample, the quantitative curve of production standard.
[result's judgement]
1. use the accompanying software of real-time fluorescence quantitative PCR instrument to carry out the preservation of file and the setting of threshold value.
2. choose the hole and the labeled standards value of different concns standard substance correspondence, use corresponding the analysis, draw typical curve and relevant information.
3. choose all samples to detect the hole, use corresponding the analysis, draw the starting template number (M) of testing sample.
4. copy number N=M * 25/3 of AFP mRNA in every milliliter of whole blood sample.
Description of drawings
Fig. 1 detects figure for sample standard.
Fig. 2 is the sample standard graphic representation.
Embodiment
Embodiment 1
The real-time fluorescence quantitative RT-PCR method detects expression and the application of human peripheral AFP mRNA
One, material:
Total RNA extraction reagent, RT and PCR damping fluid, competence bacterium (DH5 α) produces for Hefei ZhongKeDa Bioisystech Co., Ltd, DEPC (diethylpyrocarbonate) available from the .M-MLV of Biobasic company reversed transcriptive enzyme available from Invitrogen company, the Taq enzyme, Oligo (dT), the T-carrier, the regular-PCR amplification kit is available from Takara company, DTT (dithiothreitol (DTT), 0.1M) available from Invitrogen company, DNA gel extractionkit, plasmid reclaims reagent in a large number available from the clean biochemical technology of Hangzhou Wei Te company limited, 1-15K type trace high speed low temperature centrifugal machine, 2-5 type low speed normal temperature whizzer is available from German Sigma company, the hypervelocity refrigerated centrifuge is available from German Hettich company, 3111 type thermostat(t)ed water shell type CO
2Incubator is available from U.S. Forma company, Ultralow Temperature Freezer is available from Japanese SANYO company, Bechtop is available from the sincere biological plant of Shanghai intelligence company, and Biometra PCR instrument is available from Biometra company, sequencing reagent, 377 sequenators, available from U.S. Applied Biosystems company.
Two, primer and probe design and synthetic:
With the AFP full length cDNA sequence is template, use ABI7000 type real-time fluorescence quantitative PCR instrument (U.S. Applied Biosystems company) accompanying software to analyze TaqMan primer and probe site, consider AFP genomic dna sequence situation simultaneously, therefrom select best of breed.
The standard substance primer sequence is identical with the PCR primer sequence with detection, and the upstream and downstream primer sequence is respectively:
P1:5 '-TGA CTC CAG TAA ACC CTG GT-3 ', P2:5 '-AGA AAT CTG CAA TGA CAG CC-3 ', the fluorescent probe sequence is: 5 '-FAM-TGC TGC ACT TCT TCA TAT GCC AAC A-TAMRA-3 ' all has Shanghai to give birth to worker company and synthesizes.
Three, detection prepares with standard substance:
1. the extraction of cell total rna
Testing used cell is the HepG2 cell, cultivates with the RPMI1640 complete culture solution is conventional.0.25% tryptic digestion, the 1000rpm centrifugal collecting cell is transferred in the Eppendorf pipe, and every pipe has 1 * 10 approximately
6Individual cell.Operate by above-mentioned method for extracting total RNA step 6-step 12.
2. reverse transcription reaction
The centrifuge tube that reverse transcription damping fluid, dNTP mixture, reversed transcriptive enzyme storage liquid are housed is taken out from-20 ℃, place treat on the ice chest that it slowly melts after, of short duration centrifugal, with pipettor dNTP mixture and reversed transcriptive enzyme storage liquid are all added in the reverse transcription damping fluid pipe and to be mixed with inverse transcription reaction liquid, mixing, of short duration centrifugal, place on the ice chest standbyly, use back residue inverse transcription reaction liquid can put into-20 ℃ of refrigerators and preserve.
According to the form below preparation reverse transcription system
Inverse transcription reaction liquid 3.5ul
Total rna solution 2.0ul
The water 4.5ul of no RNA enzyme
The reverse transcription reaction condition: 50 ℃ 10 minutes, take out and to place on the ice chest
3.PCR amplification
(annotate: the pcr amplification agents useful for same is the regular-PCR amplification kit available from Takara company herein)
Prepare the PCR reaction solution by following composition:
Reverse transcription product 10ul
10×buffer 5.0ul
dNTPmix 4.0ul
Upstream and downstream primer 2 .0ul
Taq enzyme 0.5ul
Water 28.5ul
The PCR reaction conditions: 94 ℃ 5 minutes; (94 ℃ 15 seconds, 60 ℃ 1 minute, 72 ℃ 50 seconds, 35 circulations).
4.AFP the acquisition of amplified production:
Prepare 1.2% sepharose, with gained PCR product electrophoresis, cut the agar that contains target DNA under ultraviolet lamp, after drying with paper handkerchief, chopping is weighed, and determines the volume of glue according to the ratio of 100mg=100 μ l; Add DE-A liquid according to the ratio in the DNA gel extraction kit specification sheets, 60 ℃ of heating are melted fully; Add 0.5 times of volume in the DE-B of DE-A liquid liquid mixing, add Virahol to 20% of final volume; Aforesaid liquid is changed in the preparation pipe, and the centrifugal 1min of 3600rpm abandons filtrate after repeating once; After adding 0.5ml W1, the centrifugal 30s of 3600rpm abandons filtrate; Add 0.7ml W2, the centrifugal 30s of 3600rpm repeats once after abandoning filtrate; The centrifugal 1min of 12000rpm; The pipe of purchasing is placed new 1.5ml centrifuge tube, adds 25 μ l water or elutriants in pipe center, leave standstill 1min after, (12000rpm) centrifugal 1min DNA that can obtain to reclaim the most at a high speed.
5.AFP the clone of amplified production and evaluation:
The structure of recombinant AFP cloning vector: in the 10 μ l systems, add 1 μ lT-carrier, 4 μ l DNA samples add 5 μ l and connect buffer, 16 ℃ of connections of spending the night; Get 5 μ l and connect product, join in the 200 μ l competent cells, ice bath 40min behind the mixing places 42 ℃ of water heat-shocked 90s, ice bath 2min; The LB substratum 800 μ l that add antibiotic-free, the speed with 100-150rpm on 37 ℃ of shaking tables is mixed jolting 45min; Centrifugal back is inhaled and is removed 800 μ l supernatants, and remaining 200 μ l are coated on the LA flat board equably, is inverted cultivation 10-14 hour after keeping flat 20min for 37 ℃.
The evaluation of recombinant vectors: (extracting method of plasmid/PCR identify): observe the bacterium colony on the LA flat board, the picking bacterium colony preferably of looking goes to respectively in the Boiling tube that 5ml LA substratum is housed at random, and jolting is about 14 hours, to OD in the rearmounted 37 ℃ of shaking tables of numbering
600During ≈ 4, about 1.5ml culture is changed in the centrifuge tube, 4 ℃, the centrifugal 30s of 11000rpm is resuspended in precipitation among the alkaline lysis liquid I of 100 μ l precoolings the thermal agitation mixing; The alkaline lysis liquid II that adds the new configuration of 200 μ l, ice bath 3min behind the mixing; The alkaline lysis liquid III that adds 150 μ l precoolings puts upside down ice bath 3-5min behind the mixing; 4 ℃, supernatant is transferred in another centrifuge tube behind the centrifugal 5min of 11000rpm; Add isopyknic phenol/chloroform (1: 1), vibrate back 4 ℃, the centrifugal 2min of 11000rpm, supernatant is transferred to another centrifuge tube; Add 3M NaAc solution and 2.5 times of dehydrated alcohols of 1/10 volume, room temperature leaves standstill 10min behind the mixing; 4 ℃, abandon supernatant behind the centrifugal 10min of 11000rpm, add 1ml 70% ethanol in the precipitation, after the vibration rinsing 4 ℃, the centrifugal 2min of 11000rpm; Discard and add a small amount of dehydrated alcohol behind the supernatant liquid, 4 ℃, the centrifugal 2min of 11000rpm, discard ethanol after, room temperature leaves standstill, and behind the volatilization ethanol, adds 30 μ l dissolved in distilled water DNA.Get an amount of DNA and carry out pcr amplification, determine by electrophoretic image whether the bacterium colony of getting is desired purpose bacterium colony.
6. a large amount of extractings of plasmid:
After identifying that institute's bacterium colony is the purpose bacterium colony, get the long bacterium liquid that the purpose bacterium colony is arranged of 1ml, join in the 30ml LB substratum, shaking table is cultured to OD
600Be about 0.6, get the above-mentioned bacterium liquid of 25ml and be seeded in the 300ml LB substratum 37 ℃ of overnight incubation (300rpm).4 ℃ of following 4500rpm, 20min receives bacterium, and thalline is suspended among the STE of 200ml precooling, 4 ℃ of following 4500rpm, 20min receives bacterium, and thalline adds 9ml SolutionI, mixing adds the 1ml freshly prepared N,O-Diacetylmuramidase of 10mmol/LTris-HCl (pH8.0) (10mg/ml).Add the freshly prepared SolutionII of 10ml, mixing is 5-7 time gently, and room temperature left standstill 5 minutes, the ice-cold SolutionIII of adding 7.5ml, and mixing gently, ice bath 10 minutes, centrifugal 10 minutes of 4 ℃ of following 11000rpm get supernatant.The Virahol that adds 2/3 volume, mixing, room temperature left standstill 10 minutes, centrifugal 10 minutes of 11000rpm abandons supernatant, precipitates with 70% washing with alcohol, 8000rpm, the centrifugal recovery of 15min is with 2ml TE dissolution precipitation, the LiCl that adds 2ml 5mol/L, mixing, centrifugal 10 minutes of 10000g, supernatant discarded, with 70% washing with alcohol precipitation, evaporate to dryness.Add 300 μ l TER, dissolution precipitation is transferred to Eppendorf pipe, 37 ℃ water-bath 1-2 hour, add 300 μ l 1.6mol/L NaCl (containing 13% polyoxyethylene glycol), mixing, centrifugal 15 minutes of 4 ℃ of following 12000rpm abandon supernatant.Precipitation is dissolved among the 250 μ l TE (pH8.0), uses phenol, phenol/chloroform, each extracting of chloroform respectively once.Get supernatant, add 60 μ l 10mol/L NH
4The dehydrated alcohol of Ac and 2 times of volumes (or 95% ethanol), mixing, centrifugal 5 minutes of 4 ℃ of following 12000g abandon supernatant.120 μ l, 75% washing with alcohol precipitation, centrifugal 10 minutes of 4 ℃ of following 12000g abandon supernatant.Control dry liquids, room temperature leaves standstill to drying as far as possible.Add 100 μ l tri-distilled water dissolution precipitations, ultraviolet spectrophotometer detects the concentration and the purity of plasmid down.
7. the mensuration of plasmid sequence
The plasmid of above-mentioned preparation carries out sequencing with 377 sequenators of U.S. Applied Biosystems company.
Four, sample detects
The Patients with Primary that 21 examples are made a definite diagnosis through pathology is an experimental group, and wherein 6 examples have shifted for clinical definite; The artificial control group of 10 routine normal health.It is sample that every routine experimenter gets the fresh anticoagulation cirumferential blood of 3ml.Use test kit of the present invention and carry out the cell total rna extraction, get 2 μ l RNA, carry out reverse transcription in 10 μ l total reaction systems after, use downstream primer and probe in the enterprising performing PCR amplification of ABI company 7000 type quantitative PCR instrument with detecting, condition is 95 ℃ of sex change in 10 minutes; 95 ℃ 15 seconds, 60 ℃ were carried out 50 circulations in 1 minute.Add standard substance production standard curve simultaneously.The result handles according to typical curve through instrument and calculates the expression amount that detects sample AFP mRNA.
Experimental result
One, the preparation of standard substance
Through order-checking, the standard substance of above-mentioned design conform to expection fully, the standard substance fragments sequence of recovery following (for inserting the fragment in the T carrier):
1 AGAAATCTGC AATGACAGCC TCAAGTTGTT CCTCTGTTAT TTGTGGCTTT
51 TGCTTCACAA GGTTAATGAG AAACTCTTGC TTCATCGTTT GCAGCGCTAC
101 ACCCTGAGCT TGGCACAGAT CCTTATGGAA AATGAACTTG TCATCAGAGA
151 ATGCAGGAGG GACATATGTT TCATCCACCA CCAAGCTGCT GAAGCATGGC
201 CTCCTGTTGG CATATGAAGA AGTGCAGCAC TGGCCAACAC CAGGGTTTAC
251 TGGAGTCA
Two, sample detection:
1. standard testing result is seen Fig. 1, and typical curve is seen Fig. 2.
2.6 it is all positive that example is made a definite diagnosis patient's detected result of transfer, concrete outcome is as follows:
| Patient's numbering | Sex | Age | Sample | AFP value (copy number/milliliter whole blood) |
| 1 2 3 4 5 6 | Men and women woman man man man | 60 75 55 49 63 51 | Peripheral blood peripheral blood peripheral blood peripheral blood peripheral blood peripheral blood | 3.4×10 3 1.2×10 2 2.0×10 5 9.5×10 4 2.2×10 3 4.6×10 3 |
3.15 example is not made a definite diagnosis among the patient of transfer, and 5 examples are positive, all the other 10 examples are negative, and concrete outcome is as follows:
| Patient's numbering | Sex | Age | Sample | AFP value (copy number/milliliter whole blood) |
| 9 12 13 19 20 | Woman men and women man man | 53 69 55 54 63 | Peripheral blood peripheral blood peripheral blood peripheral blood peripheral blood | 3.3×10 2 1.1×10 3 2.0×10 2 8.3×10 2 1.4×10 3 |
4. control group 10 examples are all negative.
Claims (2)
1. alpha-fetoprotein mRNA fluorescence quantitative RT-PCR detecting kit, it is characterized by: it comprises cell pyrolysis liquid I, cell pyrolysis liquid II, RNA lavation buffer solution I, RNA lavation buffer solution II, the water of no RNA enzyme, RNA separator column, reverse transcription damping fluid, dNTP mixture, reversed transcriptive enzyme storage liquid, PCR reaction solution, probe, standard substance, reference substance; More than various solution solvent for use be water;
(1), cell pyrolysis liquid I comprises 0.1mol/L Tutofusin tris-hydrochloric acid, 0.1mol/L sodium-chlor, 0.05mol/L magnesium chloride, water; Wherein 0.1mol/L Tutofusin tris-hydrochloric acid soln is under 25 ℃ of conditions, and the pH value is 7.6;
(2), to comprise 3mol/L guanidinium isothiocyanate, 2mol/L Guanidinium hydrochloride, 0.3mol/L sodium-acetate, weightmeasurement ratio be 0.2% sodium lauryl sulphate, water to cell pyrolysis liquid II; Wherein 0.3mol/L sodium acetate soln pH value is 5.2;
(3), RNA lavation buffer solution I comprises 0.2mol/L sodium-acetate, 0.1mol/L sodium chlorate, 0.1mol/L Tutofusin tris-hydrochloric acid, water; Wherein 0.2mol/L sodium acetate soln pH value is 5.2; 0.1mol/L Tutofusin tris-hydrochloric acid soln is under 25 ℃ of conditions, the pH value is 7.5;
(4), RNA lavation buffer solution II comprises 1.2mol/L Trisodium Citrate, 0.5mol/L Tutofusin tris-hydrochloric acid, water; Wherein 0.5mol/L Tutofusin tris-hydrochloric acid soln is under 25 ℃ of conditions, and the pH value is 7.5;
(5), the water preparation method of no RNA enzyme is: add diethylpyrocarbonate to deionized water, to the volume final concentration be 0.05%, place after 10-12 hour for 22-25 ℃, 121 ℃, the 20min high pressure, 22-25 ℃ of placement is standby;
(6), the RNA separator column is a kind of silicagel column, can specificity in conjunction with RNA, and used water eluted rna reaches the purpose of separation and purification RNA;
(7), the reverse transcription damping fluid comprises 9.1 μ mol/L Oligo (dT)
12-18, 3.6U/ μ lRNA enzyme inhibitors, 72.7mmol/L dithiothreitol (DTT), 182mmol/L Tutofusin tris-hydrochloric acid, 273mmol/L Repone K, 11mmol/L magnesium chloride, water; Wherein 182mmol/L Tutofusin tris-hydrochloric acid soln is under 25 ℃ of conditions, and the pH value is 8.3;
(8), to comprise 20mmol/L Tutofusin tris-hydrochloric acid, 100mmol/L sodium-chlor, 0.1mmol/L ethylenediamine tetraacetic acid (EDTA), 1.0mmol/L dithiothreitol (DTT), volume ratio be that 50% glycerine, volume ratio are 0.01% Nonidet p-40,200U/ μ l reversed transcriptive enzyme, water to the reversed transcriptive enzyme storage liquid; Wherein 20mmol/L Tutofusin tris-hydrochloric acid soln is under 25 ℃ of conditions, and the pH value is 7.5;
(9), the dNTP mixture comprises dATP, dCTP, dGTP, dTTP, is its sodium salt-aqueous solution, pH7.0-7.5, four kinds of dNTP concentration are 10mmol/L;
(10), the PCR reaction solution comprises 18.5mmol/L Tutofusin tris-hydrochloric acid, 2.78mmol/L magnesium chloride, 92.6mmol/L Repone K, 0.37 μ mol/ L upstream and downstream primer, 0.1U/ μ l Taq enzyme, 400nmol/L dATP, 400nmol/L dCTP, 400nmol/LdGTP, 400nmol/L dTTP, water; Wherein 18.5mmol/L Tutofusin tris-hydrochloric acid soln is under 25 ℃ of conditions, and the pH value is 8.3;
The upstream and downstream primer sequence is respectively:
P1：5’-TGA CTC CAG TAA ACC CTG GT-3’
P2：5’-AGA AAT CTG CAA TGA CAG CC-3’
(11), probe is fluorescence labeling probe, its sequence is:
5’-FAM-TGC TGC ACT TCT TCA TAT GCC AAC A-TAMRA-3’
The concentration of probe is: 2 μ mol/L, TE solution dissolving, TE solution consist of 10mmol/L Tutofusin tris-hydrochloric acid, 1mmol/L ethylenediamine tetraacetic acid (EDTA), water;
(12), the sequence of standard substance is:
1 AGAAATCTGC AATGACAGCC TCAAGTTGTT CCTCTGTTAT TTGTGGCTTT
51 TGCTTCACAA GGTTAATGAG AAACTCTTGC TTCATCGTTT GCAGCGCTAC
101 ACCCTGAGCT TGGCACAGAT CCTTATGGAA AATGAACTTG TCATCAGAGA
151 ATGCAGGAGG GACATATGTT TCATCCACCA CCAAGCTGCT GAAGCATGGC
201 CTCCTGTTGG CATATGAAGA AGTGCAGCAC TGGCCAACAC CAGGGTTTAC
251 TGGAGTCA
Standard substance concentration is: 10
6Copies/ μ l, TE solution dissolving, TE solution consist of 10mmol/L Tutofusin tris-hydrochloric acid, 1mmol/L ethylenediamine tetraacetic acid (EDTA), water;
(13), reference substance is divided into positive reference substance and negative control product, positive reference substance is the sample that AFP cDNA is arranged, concentration is 10
4Copies/ μ l, the TE dissolving, the negative control product are the reverse transcription product of the total RNA of peripheral blood.
2. alpha-fetoprotein mRNA fluorescence quantitative RT-PCR detecting kit according to claim 1 is characterized in that: the specification of test kit of the present invention is 10 person-portions/box; The amount of each component is in every box: 1 bottle of cell pyrolysis liquid I, the 30ml/ bottle, 1 bottle of cell pyrolysis liquid II, the 10ml/ bottle, 1 bottle of RNA lavation buffer solution I, the 10ml/ bottle, 1 bottle of RNA lavation buffer solution II, the 3ml/ bottle, 1 bottle in no RNA enzyme water, the 2ml/ bottle, 10 of RNA separator columns, reverse transcription damping fluid 1 pipe, 27.5 μ l/ pipe, dNTP mixture 1 pipe, 5 μ l/ pipe, reversed transcriptive enzyme 1 pipe, 2.5 μ l/ pipe, PCR reaction solution 1 pipe, 216 μ l/ pipe, probe 1 pipe, 24 μ l/ pipe, standard substance 1 pipe, 10 μ l/ pipe, positive reference substance 1 pipe, 10 μ l/ pipe, negative control product 1 pipe, 10 μ l/ pipe.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100377780A CN100360684C (en) | 2005-02-01 | 2005-02-01 | Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100377780A CN100360684C (en) | 2005-02-01 | 2005-02-01 | Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1712547A CN1712547A (en) | 2005-12-28 |
| CN100360684C true CN100360684C (en) | 2008-01-09 |
Family
ID=35718341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100377780A Expired - Fee Related CN100360684C (en) | 2005-02-01 | 2005-02-01 | Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100360684C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101591650B (en) * | 2009-06-24 | 2010-12-01 | 中国人民解放军第四军医大学 | Reagent for separating RNA from biological tissue/cell/blood sample |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101586162B (en) * | 2009-06-10 | 2011-02-09 | 戴立忠 | Method of extracting target nucleic acid and performing PCR amplification |
| CN101643762B (en) * | 2009-09-02 | 2013-05-01 | 陈依军 | PCR amplification system and PCR amplification method for high GC content gene |
| CN102286473A (en) * | 2011-09-08 | 2011-12-21 | 苏州大学 | Reagent kit for directly carrying out nucleic acid amplification from whole blood sample and method |
| CN102978105A (en) * | 2012-12-24 | 2013-03-20 | 天津启仁医药科技有限公司 | mRNA (messenger ribonucleic acid) quick-extraction kit |
| CN111349693A (en) * | 2018-12-20 | 2020-06-30 | 苏州英泽生物医药科技有限公司 | Color reverse transcription premixed liquid |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262440A (en) * | 2000-01-12 | 2000-08-09 | 上海本草生物医学工程研究所 | Semi-quantitative quick-diagnosing reagent for detecting alpha-fetoglobulin and its preparing process |
| US6514685B1 (en) * | 1994-09-19 | 2003-02-04 | Ricardo J. Moro | Detection of cancer using antibodies to the alphafeto protein receptor |
| CN1410546A (en) * | 2002-11-12 | 2003-04-16 | 浙江大学医学院附属第二医院 | Real time fluorescence quantitative RT-PCR detection human alpha-fetoprotein reagent box |
-
2005
- 2005-02-01 CN CNB2005100377780A patent/CN100360684C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514685B1 (en) * | 1994-09-19 | 2003-02-04 | Ricardo J. Moro | Detection of cancer using antibodies to the alphafeto protein receptor |
| CN1262440A (en) * | 2000-01-12 | 2000-08-09 | 上海本草生物医学工程研究所 | Semi-quantitative quick-diagnosing reagent for detecting alpha-fetoglobulin and its preparing process |
| CN1410546A (en) * | 2002-11-12 | 2003-04-16 | 浙江大学医学院附属第二医院 | Real time fluorescence quantitative RT-PCR detection human alpha-fetoprotein reagent box |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101591650B (en) * | 2009-06-24 | 2010-12-01 | 中国人民解放军第四军医大学 | Reagent for separating RNA from biological tissue/cell/blood sample |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1712547A (en) | 2005-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100360684C (en) | Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA | |
| CN1324146C (en) | Fluorescent quantitative PT-PCR detection kit for detecting BCR-ABL fusion gene (P210bcr/abl)mRNA | |
| CN100371459C (en) | Kit with fluorescent quantitative RT-PCR detection technique used for cell keratin 19(Ck19)mRNA | |
| CN108342464A (en) | One-step method detects the kit and its detection method of HER2/neu gene expression amounts | |
| CN105925719A (en) | Gene related to liver cancer differentiation and application of gene | |
| CN105154541B (en) | Application of the miRNA in Diagnosing Acute Myeloid Leukemia and treatment | |
| JP7090357B2 (en) | Use of primer sets, kits, and microRNA serum markers and primer sets to identify the sex of sturgeon | |
| CN105483246B (en) | Application of the differential expression of gene in carcinoma of mouth diagnosis | |
| CN100368565C (en) | Detection kit for lung specificity X protein mRNA expression amount and its special primer and probe | |
| CN102776287B (en) | Kit for quantitatively detecting expression level of specific gene 1 mRNA (messenger Ribonucleic Acid) in human breast cancer | |
| CN105288659A (en) | Application of TENM1 gene and its expression product on diagnosis and treatment of papillary adenocarcinoma | |
| CN101215604B (en) | Kit for detecting human galactophore globin mRNA expression quantity and application thereof | |
| CN105505936B (en) | A kind of anti-bone and flesh tumor metastasis biological agent and its application | |
| CN101760518A (en) | Method for extracting live bacteria RNA in Mycobacterium tuberculosis and detection kit thereof | |
| CN103725787B (en) | Fluorescent PCR (Polymerase Chain Reaction) detection kit for fusion genes of leukemia | |
| CN109161596B (en) | The application of miR-129 and its target gene in detection adenocarcinoma of lung | |
| CN101671728B (en) | Method for detecting expression quantity of carcinoembryonic antigen mRNA and special kit thereof | |
| CN105838804A (en) | MiR-17-5p hematological malignancy auxiliary diagnosis reagent and application | |
| CN110551817A (en) | Kit for detecting human WT1 fusion gene and use method thereof | |
| CN103740835B (en) | A kind of leukemia fusion gene fluorescence PCR detection reagent kit | |
| CN113981141B (en) | A group of molecular markers in plasma of hepatitis B infected patients and carriers and application thereof | |
| CN106148561A (en) | The diagnosis and treatment label of carcinoma of prostate | |
| CN107164550A (en) | A kind of reagent for detecting myocardial infarction and its application | |
| CN107164546A (en) | MiRNA, composition and its application in diagnosing the illness | |
| CN109762897B (en) | Osteosarcoma biomarker circular RNA-circ _0006633 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ANHUI PUYUAN BIOLOGY SCIENCE CO., LTD. Free format text: FORMER OWNER: HEFEI ZHONGKEDA BIOISYSTECH CO., LTD. Effective date: 20090710 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090710 Address after: Tianda high tech Zone, Hefei Road, Anhui province No. 71 yuan Huayi Science Building 5 layer C Patentee after: Anhui Jiyuan Bio-technology Co.,Ltd. Address before: College of life science, West Central School, 96 Jinzhai Road, Anhui, Hefei Patentee before: Hefei Zhongkeda Bio-technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080109 Termination date: 20200201 |